3 Stocks to Get on Your Watchlist

I follow a large number of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time came to choose which stock I'm buying or shorting next.

Today is Watchlist Wednesday, so I'm discussing three companies that have crossed my radar in the past week. I'll also discuss at what point I may consider taking action on these calls with my own money. Keep in mind that these aren't concrete buy or sell recommendations, and I don't guarantee I'll take action on the companies being discussed, but I do promise that you can follow my real-life transactions through my profile and that I, like everyone else here at The Motley Fool, will continue to hold the integrity of our disclosure policy in the highest regard.

It's a rare day when I advocate adding an over-the-counter stock to your watchlist, but megacap Japanese automaker Nissan is a reasonable exception to the rule.

As with all automakers, the global recession really put a hurt on Nissan, causing the auto giant to turn in a loss in 2009 and only deliver a marginal profit in 2010. Within the U.S., Nissan struggled to gain traction with the resurgence of Detroit's big three and the introduction of a number of new electric vehicles and hybrids that hooked cost-conscious consumers.

But times are changing. Nissan is on fire, and it has a number of factors to thank for its recent sales surge that has pushed its U.S. market share to 8.6% from just 8% last year.

First, as Foolish senior auto analyst John Rosevear noted in March, Nissan's sales incentives for the Altima have been higher than just about any other midsize sedan in the industry. Incentives encourage consumers to buy, and if the car and brand turn out to be dependable, then these same consumers could become customers for life. Year to date, Altima sales are up 5.2% from this time last year, and the model is the 11th best-selling vehicle in the U.S. for 2014.

2014 Nissan Sentra. Source: Nissan.

Secondly, sales of the Sentra are soaring through the roof as consumers are just eating up its recent redesign and improved fuel economy. Once again cost-conscious consumers have to love the ability to get into a Sentra for well under $20,000 at a time when hourly earnings aren't increasing at a quick enough rate for most workers. Sales of the Sentra are up a whopping 41.3% year to date.

Finally, Nissan is also seeing strong growth outside the U.S. in China despite long-standing tension between the two countries. By focusing on emerging markets Nissan can tap into regions that are more resistant to global slowdowns because they can grow independently.

With Nissan valued at less than 10 times forward earnings and having a lot of wind in its sails, it's time for value investors to give the company a closer look.

Kandi Technologies (NASDAQ: KNDI  )
That's right, folks, there are two foreign automakers to get on your watchlist this week. In addition to electric vehicles, China-based Kandi Technologies also manufactures three-wheeled motorcycles, all-terrain vehicles, go-karts, and auto generators.

Source: Kandi Technologies

Kandi started the week off with a bang after it announced that its joint-venture subsidiary, Kandi Electric Vehicle Group, which is owned 50-50 by Kandi and Shanghai Maple Guorun Automobile, received a $31.8 million electric-vehicle subsidy from the Chinese government for selling more than 3,000 EV's between June and December 2013 and for moving more than 1,000 EV's during the first quarter of 2014.

On one hand, there's a lot of promise for a diversified vehicle maker like Kandi. Its affordable luxuries speak to China's burgeoning middle class, and its sales during Q1 prove this fact. During the first quarter total revenue catapulted 174% higher to $40.2 million as EV product revenue grew 384.5% and income from its aforementioned joint venture more than doubled to $1.7 million from $0.8 million.

But more than that Kandi is a long-term play on China's superior global growth prospects and the fact that China will need to implement stringent pollution controls to restrict the release of pollutant gases into its major cities. Electric vehicles are one of the many solutions to China's long-term woes, meaning Kandi could continue to see improved sales and government-sponsored subsidies for many years down the road.

On the other hand, counting on consistent subsidy payments from the Chinese government could set investors up for a disappointment. Unlike U.S. subsidies which can be accounted for with regularity, Chinese government subsidies aren't exactly paid with any promptness per my Foolish colleague Travis Hoium, who knows a thing or two about anything concerning alternative energy. In addition, this subsidy, while a nice boost to its top line, isn't guaranteed to continue, so it could mask the fact that Kandi's EPS growth is considerably more tame than its organic revenue growth would imply.

All told, this is an intriguing company with plenty of potential. It still has some hurdles to work through, including the real test of whether it can stand up to foreign EV competition when it fully enters China. In the meantime I'd suggest adding Kandi Technologies to your watchlist.

Vertex Pharmaceuticals (NASDAQ: VRTX  )
As always, I have a company short-sellers should be keeping their eyes on; and as an added change it's actually a company I've generally liked and truly hope succeeds. This would be none other than high-flying biotechnology company Vertex Pharmaceuticals.

Vertex shares have been on fire since reporting positive results from its late-stage TRAFFIC and TRANSPORT studies involving the combination of investigational compound VX-809 and its already FDA-approved drug Kalydeco in patients with cystic fibrosis (CF) that have two copies of the F508del mutation (the most common mutation of CF).

Source: Vertex Pharmaceuticals.

As noted in Vertex's press release, all four study arms demonstrated statistical significance when it came to an improvement in forced expiratory volume in one second, or FEV1, with a mean absolute improvement of between 2.6% and 4% from baseline relative to the placebo. Vertex and shareholders obviously believe the data carries weight that should allow it to file a new drug application for the combo and based on the data I'd personally suggest a better than 50% chance of approval (remember, this is the Food and Drug Administration where there are no certainties!).

But Vertex shares have gained more than $7 billion in market value since this data was released, and let's not forget that one of the key drugs that put the company on the map -- hepatitis C treatment Incivek -- is now obsolete and a has-been among blockbuster drugs. Essentially, Vertex's entire pipeline is based on its potential to treat cystic fibrosis.

The good news is that I do see a bright future over the long run for Vertex and its product portfolio of Kalydeco and VX-809. Patient quality of life should improve and Vertex shareholders have already seen some impressive gains. All in all it's a win-win in this aspect.

Yet at nearly $23 billion in market value it's basically been priced out of buyout range, and it's valued at nearly six times 2017's annual sales estimates and 14 times 2017's EPS estimates according to Wall Street firms. If this were a current year estimate I'd proclaim Vertex a possible bargain -- but we're talking about three years into the future! This assumes no issues with drug pricing, insurance coverage, competition, drug launch, and all the other intangible factors that creep in unexpectedly. It just seems like a lofty price to pay for a company that's yet to earn its new $20-billion-plus valuation. I'd suggest keeping a close eye on Vertex as I suspect there could be some downside potential over the next year or two.

Foolish roundup
Is my bullishness or bearishness misplaced? Share your thoughts in the comment section below and consider following my cue by using these links to add these companies to your free, personalized watchlist to keep up on the latest news with each company:

This Buffett pick could leave these three 3 stocks in the dust! 
Imagine a company that rents a very specific and valuable piece of machinery for $41,000 per hour (That's almost as much as the average American makes in a year!). And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click HERE to discover more about this industry-leading stock and join Buffett in his quest for a veritable landslide of profits!

Read/Post Comments (2) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 09, 2014, at 2:08 PM, spfmf14 wrote:

    Sean, regarding your comment on "whether KNDI can stand up to foreign EV competition when it fully enters China", I give you this fact, extracted from a NY Times article.."Average annual income for a family in 2012 was 13,000 renminbi, or about $2,100. When broken down by geography, the survey results showed that the average amount in Shanghai, a huge coastal city, was just over 29,000 renminbi, or $4,700, while the average in Gansu Province, far from the coast in northwest China, was 11,400 renminbi, or just under $2,000. Average family income in urban areas was about $2,600, while it was $1,600 in rural areas." Kandi is well positioned to supply the Chinese that are making in that $5,000 a year range still with automobile access, can those foreign EV makers do the same? Yes, there is a segment of Chinese that are more affluent, and any subsegment of a 1.3 billion population is still usually a significant number, but I maintain that most EV makers (not just TSLA) will be marketing to a smaller, wealthier subset, while KNDI cars are targeting a different market segment altogether, a market segment that is larger by a factor of, you name it, 100:1, or 1000:1? So I ask you, upon reflection, does your question really hold any water?

  • Report this Comment On July 09, 2014, at 5:00 PM, corstrat wrote:

    Sean, your common sense "China" perspective toward KNDI and its goals and achievements are right on. However, any risk perceived over the subsides, now that they have finally begun at the Federal level are minimal at worst

    Several months ago I visited the Company for several days and spent a lot of time with the Chairman/CEO. It is clearly his opinion that the subsidies will be in place for several years to come. At least through the end of the decade. Based on his long political history in China, I feel very comfortable he knows what he speaks of.

    However, the real irony is that had there been no subsidy program spoken of, it is likely that KNDI's total sales over the past few years would have numbered in the six digits by now.

    KNDI's Federally approved Lithium powered cars sell for at least 50% cheaper than any other approved EV's in China. IMO, the only thing that has curtailed their "organic growth" was the "carrot" of the subsides that have been inactively waved in front of consumers for almost three years until now. Much as in the case of any new product; who is going to pay full price for a product "today" when they have been told month in and month out that if they just "wait a while", they will get it much cheaper? (or in KNDI's EV case, almost for free)

    As in any long term agreement involving cash, until the first check clears, there is no assurance that any cash will be paid. Now that KNDI has received its first partial payment for the first 3000 cars, and that payment came first from the Federal PRC, a "game changer" has now been initiated. I say partial payment in that the PRC Government has mandated on its initial 25 subsidy approved cities that they must effectively "match" the PRC payment with one of their own assuming the "City" wants to stay in the Subsidy program. As mentioned in the recent KNDI PR, the Company expects the Hangzhou subsidy for just the first 3000 EV's to be coming shortly. This likely means, any day now.

    Now remember, this payment which total could likely exceed $60 million is just for the 3000+ EVs sold in late 2013 and Q1 14. As can be seen from the link below of an article titled out today in the China media: "China pure electric passenger car production Condi [KNDI] champion" We know for a fact as reported by the Government in China that KNDI has been the leader of EV's throughout all of China for the last four months and that in just April and May over 3000 cars were produced. (June's numbers have not been reported yet). Even if they did no cars in June which is highly unlikely, it appears that another $50 million plus in subsidies should be coming just for Q2 (Though not paid until now, Subsidy payments were 10% higher for cars sold in 2013)

    To put all this in perspective from a market point of view, assuming KNDI only receives $100 million in subsidies for the first half, on a percentage of Market Cap basis, this would be equivalent to TSLA getting around a $5 billion subsidy. (wonder how much TSLA would gap if they could make such an announcement?)

    With KNDI's insane Short Interest reported approaching 7 million and the likely news that should be coming just between now and up to and including Q2 earnings on Aug. 11, it should be a very exciting month ahead. And prove your "pick" of KNDI to be "Right On".

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3020445, ~/Articles/ArticleHandler.aspx, 8/27/2015 10:28:26 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated 1 hour ago Sponsored by:
DOW 16,654.77 369.26 2.27%
S&P 500 1,987.66 47.15 2.43%
NASD 4,812.71 115.17 2.45%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/27/2015 4:00 PM
KNDI $6.62 Up +0.57 +9.42%
Kandi Technologies CAPS Rating: **
NSANY $18.14 Down -0.03 -0.14%
Nissan Motor CAPS Rating: ****
VRTX $133.75 Up +3.64 +2.80%
Vertex Pharmaceuti… CAPS Rating: ****